me 26 janv - Innovation First @ BioData @ Ramada Park Hotel
BioData is the yearly Swiss symposium where leaders of the biopharmaceutical industry meet investors. BioData has been designed to inform venture capitalists, financial analysts and fund managers responsible for asset allocation of the current issues facing the biopharmaceutical industry.
Keynote lectures and panel discussions cover topics ranging from the influence of Asia's dramatic growth on the global pharma industry to the lessons that can be learnt from the success of the Swiss pharma industry. BioData will also include a strong focus on medical technology companies. Invited speakers for keynote lectures and panel discussions include senior management representatives from biotechnology companies both in Europe and the United States as well as leading investment professionals from around the globe. The fourth edition of BioData will take place at the Ramada Park Hotel in Geneva. The full program is available on the BioData web site: www.biodataforum.com
Panel in English. Tous les intervenants parleront en anglais.
Founded in April 2004, Vital-IT is a new Swiss computing centre designed to deliver the computing infrastructure necessary to support research in the life sciences. A collaborative project between the Swiss Institute of Bioinformatics, the Ludwig Institute for Cancer Research, the Swiss Federal Institute of Technology in Lausanne, the Universities of Geneva, Lausanne and Basel, Hewlett-Packard Company and Intel Corporation, Vital-IT provides large-scale computational resources to support the latest developments in fundamental and applied research. Increasingly, researchers are generating large volumes of data through multidisciplinary research projects. This session takes a first-hand look at what bioinformatics has to offer life science researchers in the years ahead. It examines closely the likely impact of Vital-IT's computing power, software development capabilities, and other expertise on both life science research in Switzerland and worldwide. What can we realistically expect from high-performance computing resources in terms of transforming biologically relevant knowledge into new technologies, applications and, ultimately, new therapeutics?
((( Dominique Gillot, Life Science manager Europe, Middle East and Africa (EMEA), Hewlett-Packard "Increasing the productivity of life science research"
The complexity of the problems faced by researchers in the life sciences calls for drastic improvements in the way the IT industry provides solutions to shorten discovery times. These improvements can come from new computing architectures taking advantage of the very latest processor technologies. They can also come from the way the huge amount of data being generated is channeled and how applications are designed and optimised. Hewlett-Packard has decided to team up with key partners like Intel and Oracle to work on this problem.This talk will describe how very strong productivity tools can help in the discovery process, not only in computing but also in file transfer and file access using global file systems like LUSTRE. This presentation will also refer to the VITAL-IT project which is the subject of a key note lecture also outlined in this program.
16:25 - 16:50
((( Jennifer Griffiths, Director, Global Business Development, Novartis Pharmaceuticals " The criteria for successful in-licensing at Novartis"
The Novartis product pipeline is one of the broadest in the industry and currently comprises a total total of 67 projects in clinical development. To develop new products, acquire platform technologies, and to access new markets, Novartis forms strategic alliances and collaborations with other partners in the industry and with academic institutions. In the course of its history, in-licensing has played an increasingly important role at the company. Across the pharmaceutical industry, biotechnology products now represent a large portion of drug pipelines. Currently, the strategic alliance arm of Novartis manages over 250 collaborations in 17 countries, over 170 of which are with leading academic centres and over 80 of which are with major biotechnology companies. In 2004 alone, the Novartis research arm has completed more than 90 pre-clinical deals. Evaluation methods and rigorously applied investment criteria are key to review technologies and to select the best pre-clinical candidates from established biotechnology companies. At Novartis, products and compounds reviewed for in-licensing are selected and rigorously evaluated by the same criteria as in-house discoveries. This talk takes a close look at these criteria as well as how they may evolve in the coming years. What can start-up companies expect in the future for a successful partnership with the pharmaceutical
industry?
16:50 - 18:00
Panel Discussion
" Switzerland : a biotechnology or medical technology country?"
The BioAlps region is home to more than 200 medical technology and biotechnology companies. For many years, the medical technology sector has been an integral part of this landscape and is increasingly attracting the attention of the investment community. How do medical technology companies compare to biotechnology companies from an investor's perspective? What are the current and future avenues of innovation that offer the most potential for delivering marketable products in the medical technology sector? If the convergence of biotechnology and medical devices is inevitable, when will it become areality? This panel discussion looks at the impact of recent developments in the medical technology sector and examines the outlook for academic institutions, start-up companies and larger corporations.
Moderated by Jacques Essinger, Executive Chairman, Symetis
With
((( Antoine Papiernik, Managing Partner, Sofinnova ((( Andre J. Mueller, Member of the Board of Directors, former CFO, Actelion ((( Robin Young, Medtech Analyst, HealthpointCapital ((( Philippe Dro, CEO, Endoart ((( Ivor Elrifi, co-chair of the Intellectual Property Section, Mintz Levin ((( Stephane Lavallee, CEO, Praxim ((( Markus Ochs, Director, Stryker
Q&A with the audience
Free admission, but registration mandatory by clicking on je m'inscris
Thanks to the main sponsors
Place
Ramada Park Hotel
Avenue Louis-Casaï 75-77
1216 Cointrin-Genève Map
BY TRAIN: 500 meters from the airport railway station
BY CAR: exit " Aéroport " follow " Genève centre " and " Balexert "
